{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000340.3:c.89G>C",
          "cDNA Change": {
            "transcript": "NM_000340.3",
            "ref": "G",
            "alt": "C",
            "position": "89"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "P",
            "position": "30"
          },
          "Description in input context": "A30P mutation"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005313"
  },
  "Experiment Method": [
    {
      "Assay Method": "Cell culture with protein aggregation and toxicity assays",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "PC12/TetOn",
        "Description": "Inducible model system using PC12/TetOn cells to study α-synuclein aggregation and toxicity."
      },
      "Readout type": "Qualitative and quantitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.89G>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Gain-of-function (increased aggregation and toxicity)",
          "Result Description": "A30P mutant showed increased aggregation and toxicity compared to wild-type α-synuclein under conditions of macroautophagy inhibition (3-MA) and proteasome inhibition (MG132)."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly mentioned in the text."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly mentioned in the text."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type α-synuclein was used as a positive control for baseline aggregation and toxicity."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector (no α-synuclein expression) was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Normal aggregation levels (e.g., no detectable insoluble protein aggregates) and no significant cytotoxicity.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Significant increase in insoluble protein aggregates and/or cytotoxicity (e.g., >50% cell death).",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}